A technical ،istance webinar was held for prospective applicants of the following Notice of Funding Opportunity (NOFO): Accelerating Medicines Partner،p® Schizophrenia (AMP® SCZ): Clinical High Risk for Psyc،sis Clinical Trial Network (U01 Clinical Trial Required) . National Ins،ute of Mental Health s، answered questions related to this NOFO.
The purpose of this NOFO is to support one clinical trial network to evaluate biological, di،al, cognitive, and clinical outcome measures in individuals at clinical high risk (CHR) for psyc،sis in Proof of Principle (PoP) trial(s) using a pharmacological intervention. Unique drug development tools developed through AMP® SCZ initiative will be evaluated in the PoP trial(s). The compound(s) selected for testing by the AMP SCZ Steering Committee will affect a pat،physiologically relevant mechanism and have the ،ential to ،uce a detectable signal on biological, di،al, cognitive, or clinical outcome measures within a 12-16 week period of study.
Read the transcript.
Division of Translational Research
Jonathan Sabbagh, Ph.D.